JP2002522039A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002522039A5 JP2002522039A5 JP2000563313A JP2000563313A JP2002522039A5 JP 2002522039 A5 JP2002522039 A5 JP 2002522039A5 JP 2000563313 A JP2000563313 A JP 2000563313A JP 2000563313 A JP2000563313 A JP 2000563313A JP 2002522039 A5 JP2002522039 A5 JP 2002522039A5
- Authority
- JP
- Japan
- Prior art keywords
- envelope protein
- hiv envelope
- antibody
- hiv
- vaccine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101710091045 Envelope protein Proteins 0.000 description 19
- 101710188315 Protein X Proteins 0.000 description 19
- 102100021696 Syncytin-1 Human genes 0.000 description 19
- 238000000034 method Methods 0.000 description 16
- 241000725303 Human immunodeficiency virus Species 0.000 description 15
- 229960005486 vaccine Drugs 0.000 description 6
- 230000036436 anti-hiv Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 125000003275 alpha amino acid group Chemical group 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 2
- 108010069514 Cyclic Peptides Proteins 0.000 description 1
- 102000001189 Cyclic Peptides Human genes 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9526798P | 1998-08-04 | 1998-08-04 | |
| US60/095,267 | 1998-08-04 | ||
| PCT/US1999/017596 WO2000007631A1 (en) | 1998-08-04 | 1999-08-04 | Expression and characterization of hiv-1 envelope protein associated with a broadly reactive neutralizing antibody response |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2002522039A JP2002522039A (ja) | 2002-07-23 |
| JP2002522039A5 true JP2002522039A5 (enExample) | 2010-01-28 |
| JP4637356B2 JP4637356B2 (ja) | 2011-02-23 |
Family
ID=22251048
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000563313A Expired - Fee Related JP4637356B2 (ja) | 1998-08-04 | 1999-08-04 | 広い反応性の中和抗体応答を伴うｈｉｖ−１エンベロープタンパク質の発現およびキャクタライゼーション |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1104310B1 (enExample) |
| JP (1) | JP4637356B2 (enExample) |
| AT (1) | ATE435034T1 (enExample) |
| AU (1) | AU762376C (enExample) |
| CA (1) | CA2338886C (enExample) |
| DE (1) | DE69941051D1 (enExample) |
| WO (1) | WO2000007631A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW511388B (en) | 2000-03-28 | 2002-11-21 | Koninkl Philips Electronics Nv | Passive radiator having mass elements |
| WO2004045495A2 (en) * | 2002-05-10 | 2004-06-03 | The Henry M. Jackson Foundation | Interacting site for gp41 on gp120 of hiv-1 |
| EP1638995B1 (de) | 2003-06-20 | 2015-08-26 | Siemens Healthcare Diagnostics Products GmbH | Neue oberflächenprotein-(hbsag-) variante des hepatitis b virus |
| US8242238B2 (en) * | 2003-06-20 | 2012-08-14 | Dade Behring Marburg Gmbh | Surface protein (HBsAg) variant of the hepatitis B virus |
| GB0417494D0 (en) | 2004-08-05 | 2004-09-08 | Glaxosmithkline Biolog Sa | Vaccine |
| CA2651764A1 (en) * | 2006-05-09 | 2007-11-22 | Gerald V. Quinnan | Hiv-1 immunogenic compositions |
| JP2011502521A (ja) * | 2007-11-12 | 2011-01-27 | ザ ヘンリー エム． ジャクソン ファウンデーション フォー ザ アドヴァンスメント オブ ミリタリー メディシン インコーポレイテッド | Ｈｉｖ−１外被糖タンパク質オリゴマー及び使用方法 |
| MX2012011189A (es) | 2010-03-26 | 2013-02-07 | Glaxosmithkline Biolog Sa | Vacuna contra el virus e inmunodeficiencia humana. |
| EP2621528A1 (en) | 2010-09-27 | 2013-08-07 | GlaxoSmithKline Biologicals S.A. | Vaccine |
| WO2014039746A1 (en) | 2012-09-07 | 2014-03-13 | Emory University | Hiv immune stimulating compositions comprising recombinantly expressed pili on bacteria and methods related thereto |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5820865A (en) * | 1988-01-26 | 1998-10-13 | The United States Of America As Represented By The Department Of Health And Human Services | Method to induce cytotoxic T Lymphocytes specific for a broad array of HIV-1 isolates using hybrid synthetic peptides |
| GB8923123D0 (en) * | 1989-10-13 | 1989-11-29 | Connaught Lab | A vaccine for human immunodeficiency virus |
| JPH06507398A (ja) * | 1991-05-14 | 1994-08-25 | リプリジェン コーポレーション | Ｈｉｖ感染治療のための異種複合抗体 |
| DE69311764T2 (de) * | 1992-05-14 | 1998-02-05 | Polymun Scient Immunbio Forsch | Peptide, die Antikörper induzieren, die genetisch divergierende HIV-1 Isolationen neutralisieren |
| GB9318901D0 (en) * | 1993-09-13 | 1993-10-27 | Centre Nat Rech Scient | Multiple branch peptide construction |
-
1999
- 1999-08-04 AT AT99940868T patent/ATE435034T1/de not_active IP Right Cessation
- 1999-08-04 AU AU54642/99A patent/AU762376C/en not_active Ceased
- 1999-08-04 DE DE69941051T patent/DE69941051D1/de not_active Expired - Lifetime
- 1999-08-04 CA CA2338886A patent/CA2338886C/en not_active Expired - Fee Related
- 1999-08-04 JP JP2000563313A patent/JP4637356B2/ja not_active Expired - Fee Related
- 1999-08-04 WO PCT/US1999/017596 patent/WO2000007631A1/en not_active Ceased
- 1999-08-04 EP EP99940868A patent/EP1104310B1/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003534351A5 (enExample) | ||
| KR960703136A (ko) | 탠덤 합성 hiv-1 펩티드들 | |
| NZ333500A (en) | Vaccines comprising HIV gp120 envelope polypeptides from vaccinees vaccinated with an earlier HIV gp120 vaccine and subsequently infected with HIV | |
| CA2020668A1 (en) | Fused or hybrid protein comprising viral antigen and lymphokine | |
| CA2413546A1 (en) | Modification of hepatitis b core antigen | |
| MY136081A (en) | Modified hiv - 1gag p17 peptide and immunogenic composition | |
| JP2002522039A5 (enExample) | ||
| JP2002533125A5 (enExample) | ||
| JPH0327400A (ja) | Ｂ型肝炎ウイルスコア抗原粒子 | |
| EP0693937A4 (en) | HIV-1 VACCINES, CORRESPONDING ANTIBODY COMPOSITIONS AND THEIR THERAPEUTIC AND PROPHYLACTIC USE | |
| CA2248667A1 (en) | Hla-a2.1 binding peptides and their uses | |
| CA2434000A1 (en) | Adjuvant viral particle | |
| JP2004537308A5 (enExample) | ||
| JP2002534481A5 (enExample) | ||
| JP2003529608A5 (enExample) | ||
| CA2337754A1 (en) | Recombinant multivalent malarial vaccine against plasmodium falciparum | |
| CN102000329B (zh) | 一种改造的非致病细菌来源的鞭毛素粘膜佐剂及制备方法 | |
| CA2084386A1 (en) | Hiv antigen | |
| CA2521038A1 (en) | Polypeptide comprising cell adhesion motif, t cell epitope and b cell epitope for inducing antibody production | |
| CA2338886A1 (en) | Expression and characterization of hiv-1 envelope protein associated with a broadly reactive neutralizing antibody response | |
| CN120305395A (zh) | mRNA-LNPs布鲁氏菌疫苗、表达载体及其制备方法 | |
| WO2003097814A3 (en) | Scytovirins and related conjugates, fusion proteins, nucleic acids, vectors, host cells, compositions, antibodies and methods of using scytovirins | |
| Li et al. | A Divalent Chikungunya and Zika Nanovaccine with Thermostable Self‐Assembly Multivalent Scaffold LS‐SUMO | |
| EP0704529A3 (en) | Vaccine against rabbit hemorrhagic disease virus | |
| WO2002069691A3 (en) | Immunogenic hiv peptides for use as reagents and vaccines |